Gilead Sciences has commenced 2026 with a demonstrably strong first quarter, reporting significant revenue growth primarily fueled by its leading…
Read More
Japan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market Impact
Japan’s latest National Health Insurance (NHI) drug price revision for Fiscal Year 2026 (FY26) has officially taken effect, ushering in…
Read More
Novo Nordisk’s Wegovy Pill Fuels Ambitious Growth Strategy Amidst Fierce Competition
Novo Nordisk’s groundbreaking oral semaglutide medication, branded as Wegovy, has emerged as a powerful financial engine, propelling the Danish pharmaceutical…
Read More
Eli Lilly Pledges $4.5 Billion to Expand Indiana Manufacturing, Bolstering US Pharmaceutical Supply Chain
Eli Lilly and Company is significantly expanding its manufacturing footprint in Indiana with a substantial $4.5 billion investment, pushing its…
Read More
Ginkgo Bioworks CEO Jason Kelly Discusses Autonomous Labs and the Future of Biopharma R&D
The biopharmaceutical industry is on the cusp of a profound transformation, driven by the burgeoning integration of artificial intelligence (AI)…
Read More
GSK Secures Promising Metabolic Oligonucleotide Therapy Rights from SiranBio in Up to $1 Billion Deal
In a significant move to bolster its pipeline and solidify its strategic focus on the complex challenges of obesity, global…
Read More
Daiichi Sankyo Partners with Waiv to Accelerate Digital Pathology Biomarker Discovery for Antibody-Drug Conjugate Programs
In a strategic move to enhance precision in oncology drug development, Japanese pharmaceutical giant Daiichi Sankyo has announced a significant…
Read More
Citius Oncology Secures Up to $36.5 Million in Debt and Equity Financing to Fuel Lymphir Commercialization
Citius Oncology has successfully secured a significant financial infusion, totaling up to $36.5 million, through a strategic combination of debt…
Read More
Navigating the Evolving Landscape of Oral Solid Dosage Development: A Framework for Enhanced Efficiency and Commercial Success
The pharmaceutical industry is witnessing a significant evolution in oral solid dosage (OSD) development, driven by an increasing demand for…
Read More
Bayer Acquires Perfuse Therapeutics for Up to $2.45 Billion to Bolster Ophthalmology Pipeline with Novel Endothelin Receptor Antagonist
Bayer AG is set to significantly expand its presence in the ophthalmology market with the acquisition of Perfuse Therapeutics, a…
Read MoreYOU MAY HAVE MISSED
